{"id":"augmentin-ceftriaxone-cefotaxime-netilmycin-tobramycin","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-5","effect":"Nausea"},{"rate":"2-5","effect":"Rash"},{"rate":"1-3","effect":"Allergic reactions"},{"rate":"1-5","effect":"Nephrotoxicity (aminoglycosides)"},{"rate":"1-3","effect":"Ototoxicity (aminoglycosides)"},{"rate":"0.1-1","effect":"Pseudomembranous colitis"}]},"_chembl":{"chemblId":"CHEMBL6067656","moleculeType":"Small molecule","molecularWeight":"1323.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Augmentin (amoxicillin-clavulanate) inhibits bacterial cell wall synthesis via beta-lactamase inhibition. Ceftriaxone and cefotaxime are third-generation cephalosporins that also inhibit cell wall synthesis. Netilmicin and tobramycin are aminoglycosides that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. Together, these agents provide broad-spectrum coverage against gram-positive, gram-negative, and some anaerobic bacteria.","oneSentence":"This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:51.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including respiratory tract infections"},{"name":"Urinary tract infections"},{"name":"Intra-abdominal infections"},{"name":"Meningitis"},{"name":"Sepsis"}]},"trialDetails":[{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT01559753","phase":"PHASE4","title":"Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic Treatment","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"1998-01","conditions":"Pneumonia Ventilator Associated","enrollment":225}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Amoxicillin","Clavulanic acid"],"phase":"marketed","status":"active","brandName":"Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin","genericName":"Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin","companyName":"Centre Hospitalier Universitaire de Besancon","companyId":"centre-hospitalier-universitaire-de-besancon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination of multiple beta-lactam antibiotics and aminoglycosides that inhibit bacterial cell wall synthesis and protein synthesis to kill a broad spectrum of bacteria. Used for Bacterial infections including respiratory tract infections, Urinary tract infections, Intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}